Tuesday, July 27

BioNTech

BioNTech, coronavirus, coronavirus vaccine, covid, Health, Healthcare, Pfizer, Science

8 weeks between shots is the’sweet spot’ for giving Pfizer’s two-dose COVID-19 vaccine, UK researchers say

Giving two doses of Pfizer's shot eight weeks apart could best protect against the Delta variant. A study found that the eight-week delay boosted immune responses higher than waiting 21 days. It's a trade-off between needing two doses and optimizing the immune response, the researchers said. See more stories on Insider's business page. LoadingSomething is loading. ...
BioNTech, Chile, Noticias, Pfizer, Pfizer/BioNTech, Salud, sinovac, vacunas

BioNTech offers 10 times more antibodies than Sinovac | Digital Trends Spanish

A study carried out by the University of Hong Kong reveals that those who received the Pfizer-BioNTech coronavirus vaccine have ten times more antibodies than those who were inoculated with Sinovac. The work also shows that the latter group generates levels of proteins to attack the virus that would be similar or lower than those produced naturally in patients who have recovered from COVID-19. According to the researchers, the study results, which were published in Lancet Microbe, suggest the need for "alternative strategies", such as booster vaccines, for those who have been immunized with Sinovac, as a way to increase antibody levels in these patients. "The difference in neutralizing antibody concentrations identified in our study could translate into substantial differences in the ef...
BioNTech, coronavirus, Delta, Health, Healthcare, Johnson & Johnson, Moderna, mRNA, Pfizer, Science, Vaccine, variant

Some experts who had Johnson & Johnson’s single-dose vaccine are now getting extra shots of Pfizer or Moderna to try to protect against the Delta variant

Some experts who got Johnson & Johnson's one-dose vaccine are topping it up with a dose of Pfizer or Moderna. They did it for extra protection against the fast-spreading Delta coronavirus variant, they said. The FDA and CDC don't recommend getting an extra shot, after a J&J vaccine or otherwise. LoadingSomething is loading. ...
BioNTech, coronavirus, Covid 19, cura, enfermedad, normalidad, Noticias, pacientes, pandemia, regreso a la normalidad, Salud, vacuna, vacunacion, vida normal

When does “normal life” return according to the founder of BioNTech? | Digital Trends Spanish

Pfizer's announcement that its coronavirus vaccine would have been more than 90 percent effective gave us all some hope regarding an eventual (albeit distant) end to the health crisis. Of course, we all have to be aware that the period that follows the application of the vaccine will not be easy, nor will it be perfect. In fact, it will be as hard and difficult as the one we have experienced during this 2020. So at least Ugur Sahin, founder of BioNTech, a German company associated with Pfizer in the development of the vaccine against COVID-19, has announced. In conversation with Sky News, the scientist pointed out that people could start getting vaccinated in the United Kingdom from next month. Of course, this would depend on whether the regulator in that territory approves the dr...
BioNTech, Covid 19, Noticias, Pfizer, Salud

Pfizer vaccine is 90% effective against COVID-19 | Digital Trends Spanish

US drugmaker Pfizer announced that its experimental vaccine to prevent COVID-19, called BNT162b2, was 90 percent effective, according to initial data from a phase 3 study. This is the first successful data from a large-scale clinical study of a coronavirus vaccine. “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides initial evidence of our vaccine's ability to prevent it, ”said Albert Bourla, President and CEO of Pfizer. "This is a victory for innovation, science and a global collaborative effort," added Ugur Sahin, co-founder and CEO of BioNTech. Pfizer and its German partner, BioNTech, stated that they had not encountered serious safety issues, so they expect to apply for the US emergency use authorization by ...
AstraZeneca, BioNTech, coronavirus, Covid 19, Cuánto costará la vacuna, Moderna, Noticias, Pfizer, precio, Salud, vacuna

How much will vaccines for coronavirus cost? | Digital Trends Spanish

The US modern laboratory, which is in stage three of developing the coronavirus vaccine, revealed the price of the doses. The biotechnology company, which received funds from the Operation Warp Speed ​​program (which in Spanish means “Maximum Speed ​​Operation”) from the United States federal government, commented that it has US $ 400 million in customer deposits for a possible supply of its vaccine mRNA-1273. According to what it has estimated and announced, Moderna will market its doses at a price of $ 40 dollars, while the wholesale price would reach between $ 32 dollars to $ 37 dollars. Getty Images / Digital Trends Graphics In any case, Moderna's CEO, Stéphane Bancel, promised during a conference call with analysts that their vaccine would be affordable. “We are wo...